Tsuchiya H, Sunayama C, Okada G, Matsuda E, Tomita K, Binder B R
Department of Orthopaedic Surgery, School of Medicine, Kanazawa University, Japan.
Anticancer Res. 1997 Jan-Feb;17(1A):313-6.
We have studied the effects of PAI-1 on the formation of metastasis using human fibrosarcoma cells and DNA transfection. A clone (1-3C), which shows low constitutive expression of PAI-1 and low metastatic potential to the lung, was selected from human fibrosarcoma cell line HT-1080. Newly-derived clones transfected with human PAI-1 cDNA showed a 3-5 fold increase in the antigen level of PAI-1. Further, these clones demonstrated a significant increase in both the number and incidence of lung metastases when inoculated into the tail vein of athymic mice. PAI-1 could be a prognostic marker and a target for understanding the physiology of metastasis, as well as for the treatment and prevention of hematogenous lung metastasis.
我们利用人纤维肉瘤细胞和DNA转染技术研究了纤溶酶原激活物抑制剂-1（PAI-1）对转移形成的影响。从人纤维肉瘤细胞系HT-1080中筛选出一个克隆（1-3C），该克隆显示PAI-1的组成性表达较低且对肺的转移潜能较低。用人类PAI-1 cDNA转染新获得的克隆显示PAI-1抗原水平增加了3至5倍。此外，当将这些克隆接种到无胸腺小鼠的尾静脉中时，它们在肺转移的数量和发生率上均显著增加。PAI-1可能是一种预后标志物，也是理解转移生理学以及治疗和预防血源性肺转移的靶点。
